Recent Investment Analysts’ Ratings Changes for Tango Therapeutics (TNGX)

A number of research firms have changed their ratings and price targets for Tango Therapeutics (NASDAQ: TNGX):

• 6/29/2026 – Tango Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/29/2026 – Tango Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $42.00 to $46.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Tango Therapeutics was upgraded by Jefferies Financial Group Inc. from “hold” to “buy”. They now have a $60.00 price target on the stock, up from $27.00.
• 6/25/2026 – Tango Therapeutics was downgraded by Raymond James Financial, Inc. to “hold”.
• 6/12/2026 – Tango Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/9/2026 – Tango Therapeutics had its price target raised by HC Wainwright from $27.00 to $66.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Tango Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $30.00 to $42.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Tango Therapeutics was given a new $36.00 price target by Mizuho.
• 6/8/2026 – Tango Therapeutics was given a new $35.00 price target by Wolfe Research. They now have an “outperform” rating on the stock.
• 6/8/2026 – Tango Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 6/8/2026 – Tango Therapeutics had its price target raised by Leerink Partners from $55.00 to $69.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – Tango Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”.
• 5/28/2026 – Tango Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/15/2026 – Tango Therapeutics had its price target raised by Mizuho from $20.00 to $30.00. They now have an “outperform” rating on the stock.

Insider Transactions at Tango Therapeutics

In other news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 119,460 shares of company stock worth $2,951,130 in the last ninety days. Corporate insiders own 6.50% of the company’s stock.

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.